Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Hypersensitivity Reaction

  Free Subscription

Articles published in Eur J Dermatol

Retrieve available abstracts of 81 articles:
HTML format

Single Articles

    October 2023
  1. MURRAY C, Ridge K, Conlon N
    Cost analysis of individualised dosing of omalizumab for the treatment of patients with chronic urticaria.
    Eur J Dermatol. 2023;33:561-562.

  2. NISHITANI K, Nakajima S, Miyake T, Kaku Y, et al
    Cutaneous sarcoidosis concomitant with xanthoma on the face.
    Eur J Dermatol. 2023;33:559-561.

  3. KAMADA H, Arakawa N, Fukui R, Tanji T, et al
    Nemolizumab-induced drug eruption in a 46-year-old male patient with atopic dermatitis.
    Eur J Dermatol. 2023;33:558-559.

  4. FIGUEIREDO C, Matos AL, Cardoso JC
    Bilateral periorbital swelling as the presenting manifestation of recurrent breast carcinoma.
    Eur J Dermatol. 2023;33:551-553.

  5. ZHENG H, Chen Y, Xu Y, Deng X, et al
    Efficacy and safety of abrocitinib for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis: update of a living systematic review and meta-analysis.
    Eur J Dermatol. 2023;33:530-543.
    PubMed     Abstract available

  6. LUGER T, Chu CY, Elgendy A, Ibrahim SBBK, et al
    Pimecrolimus 1% cream for mild-to-moderate atopic dermatitis: a systematic review and meta-analysis with a focus on children and sensitive skin areas.
    Eur J Dermatol. 2023;33:474-486.
    PubMed     Abstract available

    August 2023
  7. YAMADA M, Furuta M, Fujimoto N
    Erythema multiforme major induced by tramadol.
    Eur J Dermatol. 2023;33:437-439.

  8. TOYOSHIMA M, Nakaoji K, Hamada K, Yamanaka A, et al
    Analysis of skin aging patterns using a facial imaging system in patients with atopic dermatitis.
    Eur J Dermatol. 2023;33:383-393.
    PubMed     Abstract available

  9. ESCALANTE A, Serra-Baldrich E
    Pathogenic mechanisms underlying itch in atopic dermatitis: the emerging role of neuroimmune interactions.
    Eur J Dermatol. 2023;33:343-349.
    PubMed     Abstract available

  10. YU YY, Li JX, Zeng YP
    Scientific landscape and trend analysis of chronic urticaria: a two-decade bibliometric review.
    Eur J Dermatol. 2023;33:404-412.
    PubMed     Abstract available

  11. UOZUMI T, Serizawa N, Hagino T, Morita T, et al
    Dietary habits in Japanese patients with bullous pemphigoid: low intake of retinol.
    Eur J Dermatol. 2023;33:394-403.
    PubMed     Abstract available

    April 2023
  12. KOMAKI R, Miyagaki T, Okano T, Takeuchi S, et al
    Decreased serum placental growth factor levels in adult atopic dermatitis: a preliminary study.
    Eur J Dermatol. 2023;33:185-186.

  13. MATOS PR, Nogueira A, Gomes N, Pedrosa A, et al
    Acute generalized exanthematous pustulosis secondary to mianserin with liver involvement.
    Eur J Dermatol. 2023;33:172-174.

  14. DEYDIER N, Salvado M, Planes M, Misery L, et al
    Atopic dermatitis in 15q24 microdeletion syndrome: a social media study.
    Eur J Dermatol. 2023;33:157-159.
    PubMed     Abstract available

  15. PATSATSI A, Vakirlis E, Kanelleas A, Stefanaki I, et al
    Effect of a novel "emollient plus" formulation on mild-to-severe atopic dermatitis and other dry skin-related diseases as monotherapy or adjunctive therapy: an observational study on efficacy, tolerance and quality of life in adult patients.
    Eur J Dermatol. 2023;33:137-146.
    PubMed     Abstract available

  16. LI JX, Zeng YP
    Research interest in the usage of dupilumab for atopic dermatitis: a bibliometric analysis.
    Eur J Dermatol. 2023;33:87-100.
    PubMed     Abstract available

    February 2023
  17. MOSNIER A, Vocanson M, Lefevre MA
    Molecular profiling of skin test-induced inflammation to support the clinical diagnosis of delayed drug hypersensitivity reaction.
    Eur J Dermatol. 2023;33:64-66.

  18. LAMOUROUX C, Bertolotti-Potachin L, Charbotel B, Nosbaum A, et al
    Allergic contact dermatitis to diclofenac gel due to propylene glycol sensitization: usefulness of repeated open application tests to determine safer alternatives.
    Eur J Dermatol. 2023;33:42-43.

    November 2022
  19. ELDANI C, Darrigade AS, Beylot-Barry M, Jullie ML, et al
    Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as "toxic epidermal necrolysis-like".
    Eur J Dermatol. 2022;32:805-807.

  20. KOSAKA K, Uchiyama A, Ishikawa M, Watanabe G, et al
    Real-world effectiveness and safety of upadacitinib in Japanese patients with atopic dermatitis: a two-centre retrospective study.
    Eur J Dermatol. 2022;32:800-802.

  21. KIM J, Choi S, Choi S, Lee YI, et al
    Contact hypersensitivity and Demodex mite infestation in patients with rosacea: a retrospective cohort analysis.
    Eur J Dermatol. 2022;32:716-723.
    PubMed     Abstract available

  22. SALOMON G, Giordano-Labadie F
    Surfactant irritations and allergies.
    Eur J Dermatol. 2022;32:677-681.
    PubMed     Abstract available

    September 2022
  23. HONDA R, Suenaga A, Nakahara T, Shibata-Kikuchi S, et al
    Atopic dermatitis refractory to dupilumab but markedly responsive to baricitinib.
    Eur J Dermatol. 2022;32:649-650.

  24. STEFANOU G, Gregoriou S, Kontodimas S, Sfaelos K, et al
    Prevalence of adult self-reported atopic dermatitis in Greece: results from a nationwide survey.
    Eur J Dermatol. 2022;32:597-606.
    PubMed     Abstract available

  25. MELE-NINOT G, Serra-Baldrich E, Spertino J, Guilarte M, et al
    Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?
    Eur J Dermatol. 2022;32:629-631.
    PubMed     Abstract available

  26. SALONEN J, Remitz A, Salonen J, Lauerma A, et al
    Allergic conjunctivitis: a risk factor for recurrent herpes simplex virus infections in patients with atopic dermatitis.
    Eur J Dermatol. 2022;32:607-614.
    PubMed     Abstract available

  27. TIOTIU A, Jaussaud R
    Successful treatment with omalizumab for cold urticaria in a patient with chronic hepatitis C virus infection.
    Eur J Dermatol. 2022;32:640-641.

  28. TETART F, Gonde H, Hervouet C
    Do generic drugs cause hypersensitivity?
    Eur J Dermatol. 2022;32:571-576.
    PubMed     Abstract available

    July 2022
  29. PIOTIN A, Hacard F, Crumbach L, Nicolas JF, et al
    Anaphylaxis to chlorhexidine after taking oral medication
    Eur J Dermatol. 2022;32:551-553.

  30. BRAUN C, Patra V, Lina G, Nicolas JF, et al
    The role of skin dysbiosis in atopic dermatitis
    Eur J Dermatol. 2022;32:439-444.
    PubMed     Abstract available

  31. WOLLENBERG A, Lio P, Kleyn E, Bissonnette R, et al
    Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials
    Eur J Dermatol. 2022;32:522-529.
    PubMed     Abstract available

  32. SERRANO ORDONEZ A, Lopez Riquelme I, Perea Polak A
    sQuiz your knowledge! Persistent unilateral facial and lip swelling
    Eur J Dermatol. 2022;32:562-563.

  33. KITAYAMA S, Makino T, Kataoka K, Mori S, et al
    Valacyclovir-induced drug reaction with eosinophilia and systemic symptoms
    Eur J Dermatol. 2022;32:538-539.

  34. MARTINEZ-SAGUER I, Dominas N, Straben U, Greve J, et al
    Patients with hereditary angioedema and their treatment patterns in Germany: a Delphi consensus study
    Eur J Dermatol. 2022;32:487-494.
    PubMed     Abstract available

  35. PANKAKOSKI A, Kluger N, Sintonen H, Panelius J, et al
    Clinical manifestations and comorbidities of pemphigus: a retrospective case-control study in southern Finland
    Eur J Dermatol. 2022;32:480-486.
    PubMed     Abstract available

    May 2022
    "Prick or treat": a case of systemic reaction during intradermal tests with beta-lactams
    Eur J Dermatol. 2022;32:426-428.

  37. FUJISHIMA C, Munemoto S, Hioki C, Sasaki H, et al
    Successful dupilumab therapy for atopic dermatitis in a patient with X-linked agammaglobulinaemia
    Eur J Dermatol. 2022;32:416-417.

  38. NAKAGAWA M, Hanada M, Amano H
    Allergic contact stomatitis caused by (meth)acrylates following sensitization by artificial nails, 20 years previously
    Eur J Dermatol. 2022;32:413-415.

  39. ROLO DE MATOS P, Nogueira A, Gomes N, Costa C, et al
    Rare presentation of Wells syndrome mimicking angioedema: a case report
    Eur J Dermatol. 2022;32:411-413.

  40. ULDAHL A, Sterner T, Bruze M, Dahlin J, et al
    Atopy patch testing and associations with atopic conditions and specific IgE tests: a population-based study in adolescents
    Eur J Dermatol. 2022;32:384-393.
    PubMed     Abstract available

  41. GUILLON C, Meziani M, Abdelli S, Sigaudo Roussel D, et al
    The aryl hydrocarbon receptor pathway plays a central role in the cutaneous response to pollutants
    Eur J Dermatol. 2022;32:305-311.
    PubMed     Abstract available

    April 2022
  42. SCHUSTER B, Ziehfreund S, Schielein MC, Tizek L, et al
    Adding happiness to complement the Dermatology Quality of Life Index in psoriasis and atopic dermatitis healthcare: a cross-sectional study
    Eur J Dermatol. 2022;32:220-226.
    PubMed     Abstract available

  43. MASUDA K, Delozier AM, Kolodsick J, Buchanan A, et al
    Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysi
    Eur J Dermatol. 2022;32:237-243.
    PubMed     Abstract available

  44. STEFANIAK AA, Knecht K, Matusiak L
    sQuiz your knowledge! Non-pruritic chronic urticaria and recurrent episodes of fever
    Eur J Dermatol. 2022;32:300-301.

    February 2022
  45. VAN HALEWIJN KF, Lahnstein T, Bohnen AM, Van Den Berg PJ, et al
    Recommendations for emollients, bathing and topical corticosteroids for the treatment of atopic dermatitis: a systematic review of guidelines.
    Eur J Dermatol. 2022 Feb 21. pii: ejd.2022.4197. doi: 10.1684/ejd.2022.4197.
    PubMed     Abstract available

  46. NADA HR, Rashed LA, Shehada J, Mostafa PIN, et al
    Phosphodiesterase 4 (PDE4) gene expression in atopic dermatitis patients, before and after treatment with topical mometasone cream.
    Eur J Dermatol. 2022 Feb 15. pii: ejd.2022.4194. doi: 10.1684/ejd.2022.4194.
    PubMed     Abstract available

  47. ESCURE G, Nudel M, Terriou L, Farhat MM, et al
    Tolerance of bradykinin-releasing drugs in patients with acquired C1 inhibitor deficiency: a case series and review of the literature.
    Eur J Dermatol. 2022;32:49-55.

    January 2022
  48. LEFEVRE MA, Mosnier A
    A case of paracetamol-induced nonpigmented fixed drug eruption confirmed by a lymphocyte transformation test.
    Eur J Dermatol. 2022;32:154-156.

  49. SHEN X, Zhang W, Li X, Lu H, et al
    Association between serum IgG and Henoch-Schonlein purpura with renal involvement in children: a cross-sectional study.
    Eur J Dermatol. 2022;32:132-134.

    December 2021
  50. SALAVA A, Perala M, Juppo M, Pelkonen AS, et al
    Effective treatment of atopic dermatitis in small children significantly improves the quality of life of patients and their families.
    Eur J Dermatol. 2021 Dec 21. pii: ejd.2021.4169. doi: 10.1684/ejd.2021.4169.
    PubMed     Abstract available

  51. EGEBERG A, Anderson P, Piercy J, Massey L, et al
    Symptom burden of patients with moderate-to-severe atopic dermatitis.
    Eur J Dermatol. 2021 Dec 21. pii: ejd.2021.4166. doi: 10.1684/ejd.2021.4166.
    PubMed     Abstract available

  52. LORET L, Ninclaus V, Dendooven A, Lapeere H, et al
    Canalicular stenosis associated with dupilumab treatment for atopic dermatitis.
    Eur J Dermatol. 2021 Dec 17. pii: ejd.2021.4180. doi: 10.1684/ejd.2021.4180.

  53. CHESTER J, Kaleci S, Liberati S, Alicandro T, et al
    Atopic dermatitis associated with autoimmune, cardiovascular and mental health comorbidities: a systematic review and meta-analysis.
    Eur J Dermatol. 2021 Dec 15. pii: ejd.2021.4168. doi: 10.1684/ejd.2021.4168.
    PubMed     Abstract available

  54. LEFEVRE MA, Mohme S, Alband N, Nogueira M, et al
    Journal club: New small molecules for atopic dermatitis management.
    Eur J Dermatol. 2021;31:849-852.

  55. TRAIDL S, Heratizadeh A, Werfel T, Dressler C, et al
    Online survey to identify current challenges in atopic dermatitis management and guideline implementation in German-speaking countries.
    Eur J Dermatol. 2021;31:806-812.
    PubMed     Abstract available

  56. ROVATI C, Rossi M, Gelmetti A, Tomasi C, et al
    Impact of the COVID-19 pandemic and lockdown on the clinical response to dupilumab treatment and the psychological status of non-infected atopic patients.
    Eur J Dermatol. 2021;31:736-740.
    PubMed     Abstract available

  57. RAVAL NS, Snowden CK, De Monnin KS, Yokoyama CC, et al
    Scarring alopecia developing after mogamulizumab-associated rash.
    Eur J Dermatol. 2021;31:841-843.

  58. SUKAKUL T, Svedman C, Dahlin J, Bergendorff O, et al
    Simultaneous positive patch test reactions to neomycin and low-molecular-weight heparins: possible cross-reaction?
    Eur J Dermatol. 2021;31:741-743.
    PubMed     Abstract available

    October 2021
  59. KURIHARA K, Fujiyama T, Tokura Y, Honda T, et al
    Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment.
    Eur J Dermatol. 2021 Oct 26. pii: ejd.2021.4140. doi: 10.1684/ejd.2021.4140.

  60. KHELLAF L, Cosserat J, Calas A, Brasme H, et al
    Unusual neurological and cardiac complications of drug reaction with eosinophilia and systemic symptoms syndrome: a case report.
    Eur J Dermatol. 2021;31:652-654.

  61. FANG YH, Wei KC, Yu MS
    Improvement of erythema elevatum diutinum refractory to dapsone following treatment for underlying multiple myeloma.
    Eur J Dermatol. 2021;31:655-657.

    August 2021
  62. INGEN-HOUSZ-ORO S, Staumont-Salle D, Palladini A, Ferries L, et al
    Immunosuppressants as steroid-sparing agents for chronic DRESS: four cases.
    Eur J Dermatol. 2021;31:576-577.

    June 2021
  63. LEFEVRE MA, Nosbaum A
    Dermpath and Clinic: How to manage adverse reactions to biological agents.
    Eur J Dermatol. 2021;31:426-427.

  64. CUI Y, Shi J, Wang C, Vinturache A, et al
    Therapeutic plasma exchange combined with continuous venovenous hemofiltration in a series of pediatric patients with toxic epidermal necrolysis.
    Eur J Dermatol. 2021;31:413-415.

  65. WATABE D, Amano H
    TNF-alpha inhibitor-induced paradoxical psoriasis and erythema nodosum in a patient with ankylosing spondylitis.
    Eur J Dermatol. 2021;31:412-413.

  66. PERRON E, Viarnaud A, Marciano L, Karkouche R, et al
    Clinical and histological features of fixed drug eruption: a single-centre series of 73 cases with comparison between bullous and non-bullous forms.
    Eur J Dermatol. 2021;31:372-380.
    PubMed     Abstract available

  67. SUGINO H, Nakamura M
    Mild hypertrichosis in both upper arms around dupilumab injection sites.
    Eur J Dermatol. 2021;31:420-421.

    April 2021
  68. MORIMOTO H, Fukuchi K, Ogura Y, Ohtsuka M, et al
    Development of lichen planus following benralizumab treatment.
    Eur J Dermatol. 2021 Apr 2. pii: ejd.2021.3995. doi: 10.1684/ejd.2021.3995.

  69. GIORDANO-LABADIE F, Becherel PA, Pralong P, Outtas O, et al
    Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Eur J Dermatol. 2021;31:217-224.
    PubMed     Abstract available

    March 2021
  70. KIRSTEN N, Mohr N, Maul JT, Augustin M, et al
    Incidence of atopic conditions in people with psoriasis: a population-based analysis.
    Eur J Dermatol. 2021 Mar 1. pii: ejd.2021.3963. doi: 10.1684/ejd.2021.3963.
    PubMed     Abstract available

    February 2021
  71. BELBEZIER A, Boccon-Gibod I, Bouillet L
    Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
    Eur J Dermatol. 2021;31:86-87.

  72. KOMATSU-FUJII T, Ogawa M, Nonoyama S, Fukumoto T, et al
    Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1(R)) after nivolumab discontinuation.
    Eur J Dermatol. 2021;31:98-99.

  73. KUMANO Y, Nagai A, Sugiura K
    Erythro-papular type drug eruption caused by fosravuconazole L-lysine ethanolate.
    Eur J Dermatol. 2021;31:90-91.

  74. UGAJIN T, Namiki T, Yokozeki H
    A case of prurigo caused by hair dye containing p-phenylenediamine: histopathological findings.
    Eur J Dermatol. 2021;31:103-104.

  75. MAKIHARA-INUKAI M, Takeichi T, Ogawa-Momohara M, Muro Y, et al
    Morphea in a Crohn's disease patient undergoing ustekinumab treatment.
    Eur J Dermatol. 2021;31:96-97.

  76. FAUCON C, Bernigaud C, Sbidian E, Hue S, et al
    Essential oils as potential triggers for bullous pemphigoid? A report of two patients.
    Eur J Dermatol. 2021;31:92-93.

  77. HAYAMA K, Fujita H, Asai-Sato M, Kawana K, et al
    Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer.
    Eur J Dermatol. 2021;31:100-101.

    January 2021
  78. NAGASAWA Y, Iinuma S, Fujii M, Kanno K, et al
    Dasatinib-induced panniculitis in a patient with chronic myeloid leukaemia.
    Eur J Dermatol. 2021 Jan 25. pii: ejd.2020.3946. doi: 10.1684/ejd.2020.3946.

  79. COSTEDOAT I, Vergara R, Dousset L, Gerard E, et al
    Drug-induced bullous lichenoid eruption: a side effect of nivolumab triggered by the TLR agonist imiquimod.
    Eur J Dermatol. 2021 Jan 15. pii: ejd.2020.3951. doi: 10.1684/ejd.2020.3951.

    December 2020
  80. DANSET M, Hacard F, Jaulent C, Nosbaum A, et al
    Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
    Eur J Dermatol. 2020 Dec 18. pii: ejd.2020.3910. doi: 10.1684/ejd.2020.3910.

    November 2020
  81. KIMURA R, Sugita K, Yamamoto O
    Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Eur J Dermatol. 2020 Nov 24. pii: ejd.2020.3904. doi: 10.1684/ejd.2020.3904.

Thank you for your interest in scientific medicine.

AMEDEO Hypersensitivity Reaction is free of charge.